BR112015028257A2 - low dose pharmaceutical composition, method for treating chronic iron overload, method for treating lead toxicity, process for preparing a low dose pharmaceutical composition and process - Google Patents
low dose pharmaceutical composition, method for treating chronic iron overload, method for treating lead toxicity, process for preparing a low dose pharmaceutical composition and processInfo
- Publication number
- BR112015028257A2 BR112015028257A2 BR112015028257A BR112015028257A BR112015028257A2 BR 112015028257 A2 BR112015028257 A2 BR 112015028257A2 BR 112015028257 A BR112015028257 A BR 112015028257A BR 112015028257 A BR112015028257 A BR 112015028257A BR 112015028257 A2 BR112015028257 A2 BR 112015028257A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- low dose
- dose pharmaceutical
- treating
- preparing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2014/051400 WO2014181108A1 (en) | 2013-05-10 | 2014-05-08 | Low dose pharmaceutical composition |
| IN1696MU2013 IN2013MU01696A (en) | 2013-05-10 | 2014-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015028257A2 true BR112015028257A2 (en) | 2017-07-25 |
Family
ID=50979804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015028257A BR112015028257A2 (en) | 2013-05-10 | 2014-05-08 | low dose pharmaceutical composition, method for treating chronic iron overload, method for treating lead toxicity, process for preparing a low dose pharmaceutical composition and process |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20160120847A1 (en) |
| EP (1) | EP2994131A1 (en) |
| JP (1) | JP2016518398A (en) |
| CN (1) | CN105377256A (en) |
| AP (1) | AP2015008875A0 (en) |
| AU (1) | AU2014264421A1 (en) |
| BR (1) | BR112015028257A2 (en) |
| CA (1) | CA2911671A1 (en) |
| EC (1) | ECSP15051434A (en) |
| HK (1) | HK1215191A1 (en) |
| IN (1) | IN2013MU01696A (en) |
| MX (1) | MX2015015553A (en) |
| PE (1) | PE20151934A1 (en) |
| PH (1) | PH12015502557A1 (en) |
| RU (1) | RU2015149544A (en) |
| SG (1) | SG11201509308TA (en) |
| WO (1) | WO2014181108A1 (en) |
| ZA (1) | ZA201403276B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10265301B2 (en) * | 2015-06-17 | 2019-04-23 | Dispersol Technologies, Llc | Formulations of deferasirox and methods of making the same |
| RU2616267C1 (en) * | 2016-01-25 | 2017-04-13 | Закрытое Акционерное Общество "БИОКОМ" | Solid drug form of indinavir with immediate release and method of obtaining thereof |
| WO2017158559A1 (en) * | 2016-03-17 | 2017-09-21 | Lupin Limited | Compositions of deferasirox |
| CN105853367B (en) * | 2016-05-10 | 2019-07-12 | 广州加德恩医药有限公司 | The preparation method and its pharmaceutical preparation of Deferasirox solid dispersions |
| CA3029543C (en) * | 2016-07-05 | 2021-11-23 | Jubilant Generics Limited | Immediate release pharmaceutical composition of iron chelating agents |
| CZ2017255A3 (en) * | 2017-05-04 | 2018-11-14 | Zentiva, K.S. | Film-coated Deferasirox tablets |
| WO2018230713A1 (en) * | 2017-06-16 | 2018-12-20 | 学校法人同志社 | Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent |
| JP6537092B2 (en) | 2017-06-16 | 2019-07-03 | 学校法人同志社 | Medicaments for treating or preventing ocular conditions, disorders or diseases, including mTOR inhibitors and applications thereof |
| CA3077514C (en) * | 2017-10-25 | 2022-10-11 | Chiesi Farmaceutici S.P.A. | Delayed release deferiprone tablets and methods of using the same |
| CN109646423A (en) * | 2018-12-03 | 2019-04-19 | 泓博元生命科技（深圳）有限公司 | Boiomacromolecule nanosphere containing NADH and the preparation method and application thereof |
| CN115154428B (en) * | 2022-09-06 | 2023-01-10 | 上海奥科达医药科技股份有限公司 | Deferasirox pharmaceutical composition and preparation method thereof |
| CN115400088B (en) * | 2022-09-06 | 2023-07-07 | 上海奥科达医药科技股份有限公司 | Dila Luo Siyao composition and preparation method thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY129541A (en) * | 1996-06-25 | 2007-04-30 | Novartis Ag | Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
| GB0223978D0 (en) * | 2002-10-15 | 2002-11-20 | Novartis Ag | Organic compound |
| GB0408078D0 (en) | 2004-04-08 | 2004-05-12 | Novartis Ag | Organic compounds |
| CA2625112A1 (en) * | 2005-10-19 | 2007-04-26 | Novartis Ag | Dispersible tablets comprising deferasirox |
| WO2009016359A1 (en) * | 2007-07-27 | 2009-02-05 | Pliva Hrvatska D.O.O. | New forms of deferasirox |
| WO2009067557A1 (en) | 2007-11-19 | 2009-05-28 | Teva Pharmaceutical Industries Ltd. | Deferasirox pharmaceutical compositions |
| WO2010035282A1 (en) | 2008-09-24 | 2010-04-01 | Matrix Laboratories Limited | Pharmaceutical compositions comprising deferasirox |
| CA2812505A1 (en) | 2010-10-01 | 2012-04-05 | Cipla Limited | Pharmaceutical composition |
| WO2013041730A1 (en) * | 2011-09-23 | 2013-03-28 | Universität Stuttgart Please note that the status of the person identified in Box 1 changed from Applicant for all designated States except US to Applicant for all designated States. | Serum half-life extension using immunoglobulin binding domains |
-
2014
- 2014-05-08 CA CA2911671A patent/CA2911671A1/en not_active Abandoned
- 2014-05-08 RU RU2015149544A patent/RU2015149544A/en not_active Application Discontinuation
- 2014-05-08 MX MX2015015553A patent/MX2015015553A/en unknown
- 2014-05-08 JP JP2016512416A patent/JP2016518398A/en active Pending
- 2014-05-08 IN IN1696MU2013 patent/IN2013MU01696A/en unknown
- 2014-05-08 ZA ZA2014/03276A patent/ZA201403276B/en unknown
- 2014-05-08 US US14/890,235 patent/US20160120847A1/en not_active Abandoned
- 2014-05-08 AP AP2015008875A patent/AP2015008875A0/en unknown
- 2014-05-08 WO PCT/GB2014/051400 patent/WO2014181108A1/en active Application Filing
- 2014-05-08 PE PE2015002380A patent/PE20151934A1/en not_active Application Discontinuation
- 2014-05-08 BR BR112015028257A patent/BR112015028257A2/en not_active IP Right Cessation
- 2014-05-08 AU AU2014264421A patent/AU2014264421A1/en not_active Abandoned
- 2014-05-08 EP EP14731760.6A patent/EP2994131A1/en not_active Withdrawn
- 2014-05-08 SG SG11201509308TA patent/SG11201509308TA/en unknown
- 2014-05-08 CN CN201480038832.0A patent/CN105377256A/en active Pending
-
2015
- 2015-11-10 PH PH12015502557A patent/PH12015502557A1/en unknown
- 2015-12-10 EC ECIEPI201551434A patent/ECSP15051434A/en unknown
-
2016
- 2016-02-18 US US15/047,091 patent/US20160158202A1/en not_active Abandoned
- 2016-03-21 HK HK16103262.7A patent/HK1215191A1/en unknown
- 2016-10-12 US US15/291,728 patent/US20170095453A1/en not_active Abandoned
-
2017
- 2017-07-14 US US15/650,195 patent/US20170312254A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PH12015502557A1 (en) | 2016-02-22 |
| ECSP15051434A (en) | 2017-05-31 |
| SG11201509308TA (en) | 2015-12-30 |
| AU2014264421A1 (en) | 2015-12-03 |
| US20170095453A1 (en) | 2017-04-06 |
| WO2014181108A1 (en) | 2014-11-13 |
| RU2015149544A (en) | 2017-06-16 |
| US20170312254A1 (en) | 2017-11-02 |
| IN2013MU01696A (en) | 2015-06-26 |
| AP2015008875A0 (en) | 2015-11-30 |
| JP2016518398A (en) | 2016-06-23 |
| CA2911671A1 (en) | 2014-11-13 |
| MX2015015553A (en) | 2016-06-17 |
| US20160158202A1 (en) | 2016-06-09 |
| CN105377256A (en) | 2016-03-02 |
| ZA201403276B (en) | 2015-07-29 |
| PE20151934A1 (en) | 2015-12-26 |
| US20160120847A1 (en) | 2016-05-05 |
| HK1215191A1 (en) | 2016-08-19 |
| EP2994131A1 (en) | 2016-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015028257A2 (en) | low dose pharmaceutical composition, method for treating chronic iron overload, method for treating lead toxicity, process for preparing a low dose pharmaceutical composition and process | |
| HK1215378A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| BR112016014014A2 (en) | composition, method for producing a compound and method for treating a material | |
| PL3349758T3 (en) | Methods for treating arenaviridae virus infections | |
| EP3263132C0 (en) | Composition for treating il-6-related diseases | |
| BR112015001098A2 (en) | compound, pharmaceutical composition and method for treating a disease condition. | |
| BR112013007276A2 (en) | pharmaceutical composition, process for preparing a pharmaceutical composition, use of pharmaceutical composition and method for treating chronic iron overload | |
| BR112016008939A2 (en) | METHOD FOR THE TREATMENT OF LIGNIN AND FOR THE PRODUCTION OF A BINDING COMPOSITION | |
| BR112014031896A2 (en) | compound, pharmaceutical composition, and method for treating a disorder | |
| HRP20190573T1 (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| HK1210806A1 (en) | Method for manufacturing immunocyte-containing composition, and cancer-treating composition | |
| AP2015008599A0 (en) | Pharmaceutical composition for treating headache, and preparation method thereof | |
| HK1247827A1 (en) | Healing topical composition | |
| BR112014031899A8 (en) | compound, pharmaceutical composition, and method for treating a disorder | |
| SMT201500214B (en) | New pharmaceutical composition for treating fungal infections | |
| BR112015002493A2 (en) | compound, pharmaceutical composition, method for treating cancer, process for preparing a pharmaceutical composition, assembly, use of a compound and invention. | |
| BR112015006641A2 (en) | fixed dose pharmaceutical composition, use of a fixed dose pharmaceutical composition, method for treating chronic iron overload and process for preparing a fixed dose pharmaceutical composition | |
| BR112014031785A2 (en) | compound, pharmaceutical composition, use of the compound, method for treating cancer and invention | |
| BR112016009727A2 (en) | process for preparing an etheramine mixture, and composition | |
| EP3020399A4 (en) | Novel pharmaceutical composition for preventing or treating cancer | |
| IL251456A0 (en) | Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component | |
| EP2905278A4 (en) | Heteroaromatic compounds, method for preparing the compounds, pharmaceutical compositions, uses and method for treating acute and chronic pain | |
| EP2970153A4 (en) | Triazine compounds and compositions thereof and methods for treating malaria and chemoprophylaxis | |
| PT3142749T (en) | Viscosupplement composition comprising ulvan for treating arthritis | |
| GB201522960D0 (en) | Chinese medicinal composition for treating acne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2513 DE 06-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |